摘要
目的:探讨可溶性程序性死亡因子配体-1(sPD-L1)与血管内皮生长因子(VEGF)在急性髓系白血病(AML)患者血清中的表达及二者的相关性。方法:选取2016年1月~2017年10月就诊于佳木斯大学第一附属医院的36例初发未治急性髓系白血病患者作为AML初治组,经过1~2个标准化疗后,27例完全缓解作为完全缓解组,9例未缓解作为未缓解组。同期选取20例我院体检中心健康体检者作为健康对照组。采用酶联免疫法(ELISA)检测所有实验对象血清中sPD-L1及VEGF的表达水平。结果:初发组及未缓解组AML患者血清中sPD-L1及VEGF的表达较健康对照组均升高明显,且差异有统计学意义(P<0.05);经过1~2个标准化疗后完全缓解组患者血清中sPD-L1及VEGF的表达较初治组下降明显,差异有统计学意义(P<0.05);完全缓解组与正常对照组比较,差异无统计学意义(P>0.05);二者的表达呈显著正相关。结论:患者血清中sPD-L1及VEGF的高表达,可能与AML的发生、发展及预后相关。因此联合检测sPD-L1及VEGF对AML患者的早期诊断、监测疗效和预后评估具有一定意义。
Objective:To investigate the expression level and correlation of soluble programmed death factor(sPD-L1)and vascular endothelial growth factor(VEGF)in serum of patients with acute myeloid leukemia.Methods:From January 2016 to October 2017 in the first affiliated hospital of Jiamusi university of 36 cases of incipient did not treat patients with acute myeloid leukemia as at the beginning of AML group,after 1-2 standard chemotherapy,27 cases with complete remission as complete remission group,9 cases did not ease as a group.In the same period,20 healthy patients were selected as the healthy control group.The expression levels of sPD-L1 and VEGF were detected by enzyme-linked immunoassay(ELISA).Results:The expression of sPD-L1 and VEGF in serum of the initial and unrelieved AML patients was significantly higher than that in the healthy control group,and the difference was statistically significant(P<0.05).After 1-2 standard chemotherapy,the expression of sPD-L1 and VEGF in the serum of patients with complete remission was significantly lower than that in the initial treatment group,and the difference was statistically significant(P<0.05).There was no statistically significant difference between the total relief group and the control group(P>0.05).There is a significant positive correlation between the two expressions.Conclusion:The high expression of sPD-L1 and VEGF in serum may be related to the occurrence,development and prognosis of AML.Therefore,the joint detection of sPD-L1 and VEGF is of some significance to the early diagnosis,monitoring efficacy and prognosis of AML patients.
出处
《海南医学院学报》
CAS
2018年第4期512-514,518,共4页
Journal of Hainan Medical University
基金
黑龙江省卫生计生委科研课题(2017-378)~~